Due to the large-scale sequencing efforts, there is currently a better understanding of the genomic landscape of several malignancies, for example, the incidence of germline BRCA mutations in newly diagnosed prostate cancer patients is 1.2–2%, and the BRCA1/2 carriers can have around 4- and 8-fold risk of developing prostate cancer, respectively. The gene discussed is BRCA1; the disease is prostate carcinoma.